Skip to main content
. Author manuscript; available in PMC: 2012 Aug 1.
Published in final edited form as: Pharmacogenet Genomics. 2011 Aug;21(8):516–521. doi: 10.1097/FPC.0b013e3283406323

Fig. 1.

Fig. 1

Effects of antiplatelet drugs in platelet aggregation pathway. (PA154444041; http://www.pharmgkb.org/do/serve?objId=PA154444041&objCls=Pathway). AA, arachidonic acid; cAMP, cyclic AMP; GNAS, guanine nucleotide binding protein a s; IP3, inositol 1,4,5-trisphosphate; PGD2, prostaglandin D2; PGE2, prostaglandin E2; PGG2, prostaglandin G2, PGH2, prostaglandin H2; PGI2, prostaglandin I2; PTGS1, prostaglandin (PG)-endoperoxide synthase 1; PLA2, phospholipase A2; TBXA2, thromboxane A2; TBXA2R, TBXA2 receptor; VWF, von Willebrand factor.